Article
Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination
Dermatology
Division
South Atlantic
Hospital
Orange Park Medical Center
Document Type
Case Report
Publication Date
5-1-2022
Keywords
- Pemphigoid,
- Bullous Pemphigoid,
- BP,
- COVID-19 vaccine adverse effects,
- SARS-CoV-2,
- COVID-19,
- Moderna COVID-19 mRNA vaccine,
- autoimmune bullous disease,
- anti-laminin gamma-1 (p200) pemphigoid,
- p200 pemphigoid
Disciplines
Abstract
As the SARS-CoV-2 vaccinated population increases, there have been many reports of vaccine-induced cutaneous reactions but scarce information on vaccine-induced autoimmune bullous disease. Vaccinations have been associated with the unmasking or development of autoimmune bullous disease; however, there is little data on SARS-CoV-2, specifically. We report a rare case of new-onset pemphigoid in a 70-year-old male following the second dose of the mRNA-1273 vaccine. The patient’s disease has been refractory to treatment, thus the underlying pathophysiology in vaccine-induced pemphigoid is likely unique, and further investigation into this pathophysiology is warranted.
Publisher or Conference
Skin: The Journal of Cutaneous Medicine
Citation Information
Altmann S, Jacobs D, Brown T, Kamath P, Krishnamurthy K. Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination. SKIN. 2022;6(3):238-242. doi:10.25251/skin.6.3.10